Skip to main content

Table 4 Medium potency estrogen-progestin therapy and risk of ductal and lobular breast cancer stratified by body mass index

From: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study

Recent BMI Control group Ductal cancer Lobular cancer
  Never use Ever use Never use Ever use Never use Ever use
  No. No. No. ORa (95%CI) No. ORa (95%CI) No. ORa (95%CI) No. ORa (95%CI)
BMI <22 298 47 126 1.0 (Ref) 49 2.0 (1.2–3.3) 19 1.0 (Ref) 12 3.4 (1.4–8.3)
BMI 22–27 895 132 420 1.1 (0.9–1.4) 114 1.6 (1.1–2.3) 46 0.8 (0.4–1.4) 21 2.2 (1.0–4.6)
BMI >27 514 53 357 1.8 (1.4–2.3) 52 1.9 (1.2–3.1) 56 1.9 (1.1–3.3) 10 2.2 (0.9–5.6)
  1. Exclusive use of medium potency estrogen-progestin therapy, users of more than one kind of menopausal hormone therapy were excluded. Women with unknown age at menopause were excluded. Recent = one year before data collection. aAdjusted for age, age at first birth and age at menopause. BMI, body mass index; CI, confidence interval; OR, odds ratio; Ref, reference category.